Literature DB >> 30925614

Alzheimer's Disease Including Focal Presentations.

Nicolas Villain1,2,3, Bruno Dubois2,3.   

Abstract

Alzheimer's disease (AD) is the commonest neurodegenerative disease and the most frequent cause of dementia. It affects 30 million people worldwide. Current research criteria focus on biomarkers' status for amyloid and tau using positron emission tomography and cerebrospinal fluid analysis, independent of clinical status. Current epidemiological data, which mostly rely on biomarker-undetermined AD cases, have highlighted ApoE4 and age as the main risk factors. Rare autosomal dominant mutations also account for a small fraction of early-onset AD. The main clinical phenotype at presentation is the amnestic phenotype targeting episodic memory. This is followed by rarer phenotypes such as posterior cortical atrophy, logopenic variant of primary progressive aphasia, frontal variant AD, corticobasal syndrome, and other even rarer presentations mimicking language variants of frontotemporal dementia. Main differential diagnoses include hippocampal sclerosis with TDP-43, primary age-related tauopathy, argyrophilic grain disease, frontotemporal lobar degeneration, Lewy body disease, chronic traumatic encephalopathy as well as nondegenerative disorders such as cerebrovascular disease, chronic alcohol consumption, limbic encephalitis, medial temporal lobe epilepsy, and others. Co-occurrence of AD pathology with other neurodegenerative and vascular diseases is common and increases with age. This presents a challenge in current clinical practice due to a lack of reliable biomarkers for non-AD neurodegenerative diseases. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Year:  2019        PMID: 30925614     DOI: 10.1055/s-0039-1681041

Source DB:  PubMed          Journal:  Semin Neurol        ISSN: 0271-8235            Impact factor:   3.420


  20 in total

Review 1.  Recent update on the heterogeneity of the Alzheimer's disease spectrum.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2021-12-17       Impact factor: 3.575

Review 2.  Aduhelm, a novel anti-amyloid monoclonal antibody, for the treatment of Alzheimer's Disease: A comprehensive review.

Authors:  Hannah W Haddad; Garett W Malone; Nicholas J Comardelle; Arielle E Degueure; Salomon Poliwoda; Rachel J Kaye; Kevin S Murnane; Adam M Kaye; Alan D Kaye
Journal:  Health Psychol Res       Date:  2022-07-28

3.  Aducanumab, a Novel Anti-Amyloid Monoclonal Antibody, for the Treatment of Alzheimer's Disease: A Comprehensive Review.

Authors:  Hannah W Haddad; Garett W Malone; Nicholas J Comardelle; Arielle E Degueure; Adam M Kaye; Alan D Kaye
Journal:  Health Psychol Res       Date:  2022-01-30

4.  The Risk of Developing Alzheimer's Disease and Parkinson's Disease in Patients with Inflammatory Bowel Disease: A Meta-Analysis.

Authors:  Marta Szandruk-Bender; Benita Wiatrak; Adam Szeląg
Journal:  J Clin Med       Date:  2022-06-27       Impact factor: 4.964

Review 5.  Depression as a Risk Factor for Alzheimer's Disease: A Systematic Review of Longitudinal Meta-Analyses.

Authors:  Olalla Sáiz-Vázquez; Patricia Gracia-García; Silvia Ubillos-Landa; Alicia Puente-Martínez; Silvia Casado-Yusta; Beatriz Olaya; Javier Santabárbara
Journal:  J Clin Med       Date:  2021-04-21       Impact factor: 4.241

Review 6.  The existence of Aβ strains and their potential for driving phenotypic heterogeneity in Alzheimer's disease.

Authors:  Heather H C Lau; Martin Ingelsson; Joel C Watts
Journal:  Acta Neuropathol       Date:  2020-08-02       Impact factor: 17.088

Review 7.  Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group.

Authors:  Bruno Dubois; Nicolas Villain; Giovanni B Frisoni; Gil D Rabinovici; Marwan Sabbagh; Stefano Cappa; Alexandre Bejanin; Stéphanie Bombois; Stéphane Epelbaum; Marc Teichmann; Marie-Odile Habert; Agneta Nordberg; Kaj Blennow; Douglas Galasko; Yaakov Stern; Christopher C Rowe; Stephen Salloway; Lon S Schneider; Jeffrey L Cummings; Howard H Feldman
Journal:  Lancet Neurol       Date:  2021-04-29       Impact factor: 59.935

Review 8.  EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease.

Authors:  Vladimir Khavinson; Natalia Linkova; Ekaterina Kozhevnikova; Svetlana Trofimova
Journal:  Molecules       Date:  2020-12-31       Impact factor: 4.411

9.  Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimer's Disease and Other Neurological Disorders.

Authors:  Giovanni Bellomo; Antonio Indaco; Davide Chiasserini; Emanuela Maderna; Federico Paolini Paoletti; Lorenzo Gaetani; Silvia Paciotti; Maya Petricciuolo; Fabrizio Tagliavini; Giorgio Giaccone; Lucilla Parnetti; Giuseppe Di Fede
Journal:  Front Neurosci       Date:  2021-03-31       Impact factor: 4.677

10.  Screening and Identification of Potential Peripheral Blood Biomarkers for Alzheimer's Disease Based on Bioinformatics Analysis.

Authors:  Xin Wang; Lantao Wang
Journal:  Med Sci Monit       Date:  2020-08-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.